Zomedica Corp.

As of March 1, 2022, Zomedica Corp. is rated as "risky" and appears overvalued with key metrics indicating a lack of profitability, including a Price to Book Value of 0.33 and a P/E ratio of -2.71, suggesting significant risk compared to its peers.

As of March 1, 2022, Zomedica Corp. is rated "risky" and considered overvalued due to poor financial metrics, including a Price to Book Value of 0.33, an EV to EBITDA of 0.77, a negative ROE of -22.48%, and a year-to-date stock return of -65.00%, significantly underperforming the S&P 500.

As of June 9, 2025, Zomedica Corp. shows a mildly bearish trend due to daily moving averages and monthly indicators signaling bearish momentum, despite some mixed signals from weekly indicators.

As of March 2022, Zomedica Corp.'s management team includes Chairman Jeffrey Rowe, CEO Robert Cohen, Chief Medical Officer Dr. William MacArthur, and several independent directors, including Dr. Jane Eagleson and Dr. Johnny Powers, among others. They oversee the company's strategic direction and operations.

Zomedica Corp. is a veterinary diagnostic and pharmaceutical company focused on companion animals, with recent quarterly net sales of $7 million and a net loss of $64 million. The company has a market cap of $41.65 million and no dividend yield.

As of Jun 18, Zomedica Corp. has a market capitalization of 41.65 million, with net sales of 27.53 million and a net profit of -101.63 million over the latest four quarters. As of December 2024, the company reported shareholder's funds of 195.66 million and total assets of 207.36 million.